Global Epilepsy Market Research Report Forecast to 2023


SKU: 190762 Categories: , Tag:


Epilepsy is a disorder of the brain characterized by repeated seizures. A seizure is usually defined as a sudden alteration of behavior due to a temporary change in the electrical functioning of the brain. Normally, the brain continuously develops tiny electrical impulse in an orderly pattern. The rising prevalence of epilepsy diseases and increasing healthcare expenditure drive the growth of the market. However, high per patient treatment cost and regulatory restriction on profitability may hamper the growth of the market.
The global epilepsy market is expected to register a CAGR of 8.20% during the forecast period of 2018 to 2023. In 2017, the market was led by the Americas with a 38.1% share. The market growth in this region is mainly due to the increasing prevalence of epilepsy disorders among the geriatric population. According to the statistics published by the Epilepsy Foundation of America Organization, 1.3 to 2.8 million people were diagnosed with epilepsy disease in the US in 2018.
The global epilepsy market has been segmented based on condition, diagnosis and treatment, end user, and region.
The condition segment is further segmented into drug-resistant epilepsy and others.
The global epilepsy market, by diagnosis and treatment, is segmented into diagnosis and treatment.
The global epilepsy market, by end user, is segmented into hospitals, clinics (family practitioners/ internal medicine), ambulatory surgical centers (outpatient centers), diagnostic centers, and others.

Key Players
LivaNova PLC, GlaxoSmithKline PLC, Eisai Co. Ltd, Pfizer Inc., Medtronic PLC, UCB SA, NeuroPace Inc, GW Pharmaceuticals PLC, Novartis AG, Johnson & Johnson Services Inc., Abbott Laboratories, and others.
Study Objectives
• To provide a detailed analysis of the market structure along with the forecast of various segments and sub-segments of the epilepsy market
• To provide insights into factors affecting the market growth
• To analyze the global epilepsy market based on various tools such as supply chain analysis and Porter’s five force analysis
• To provide historical and forecast revenue of market segments and sub-segments with respect to regions and their respective key countries
• To provide country-level analysis of the market with respect to the current market size and future perspective
• To provide country-level analysis of the market for segments by condition, diagnosis and treatment, end user, and region
• To provide strategic profiling of key players in the market, comprehensively analyzing their core competencies and drawing a competitive landscape for the market
• To track and analyze competitive developments such as joint ventures, strategic alliances, mergers and acquisitions, new product developments, and research and developments in the epilepsy market
Target Audience
• Biotechnology Companies
• Pharmaceutical Companies
• Government Research Institutes
• Academic Institutes and Universities

Key Findings
• The global epilepsy market is expected to reach USD 9,509.20 million by 2023 from USD 5,931.74 million in 2017 and is expected to register a CAGR of 8.20% during the forecast period from 2018 to 2023
• On the basis of condition, the drug-resistant epilepsy segment accounted for the largest market share and is projected to register a CAGR of 9.07% from 2018 to 2023
• Based on diagnosis and treatment, the treatment segment accounted for the largest market share and is anticipated to register a CAGR of 7.91% by the year 2023
• Based on end user, the hospitals segment held the largest market share of 29.3% in 2017 and is projected to register a CAGR of 8.29% during the forecast period
• The Americas is expected to hold the largest share of the global epilepsy market at a CAGR of 7.77% by 2023
• Asia-Pacific is the fastest growing market, which is expected to register a CAGR of 8.86% by 2023
Regional Analysis
• Americas
o North America
 US
 Canada
o Latin America
 Brazil
 Rest of Latin America
• Europe
o Western Europe
 Germany
 France
 UK
 Italy
 Spain
 Rest of Western Europe
o Eastern Europe
• Asia-Pacific
o Japan
o China
o India
o Australia
o South Korea
o Rest of Asia-Pacific
• Middle East & Africa
o Middle East
 Saudi Arabia
 Rest of the Middle East
o Africa

Table of Contents

Table of Contents:

1 Report Prologue
2 Executive Summary
3 Market Introduction
3.1 Definition
3.2 Scope of the Study
3.3 Assumptions & Limitations
3.3.1 Assumptions
3.3.2 Limitations
3.4 Market Structure
4 Research Methodology
4.1 Research Process
4.2 Primary Research
4.3 Secondary Research
4.4 Market Size Estimation
4.5 Forecast Model
5 Market Dynamics
5.1 Introduction
5.2 Drivers
5.2.1 Rising prevalence of epilepsy amongst the geriatric population
5.2.2 Increasing cases of brain injuries due to road accidents
5.2.3 Rising neurological disorders
5.2.4 Increasing research funding in epilepsy
5.3 Restraints
5.3.1 Loss of patent protection for branded drugs
5.3.2 High costs associated with the treatment of epilepsy
5.4 Opportunities
5.4.1 Entering developing economies
6 Market Factor Analysis
6.1 Porter’s Five Forces Analysis
6.1.1 Bargaining Power of Suppliers
6.1.2 Bargaining Power of Buyers
6.1.3 Threat of New Entrants
6.1.4 Threat of Substitutes
6.1.5 Intensity of Rivalry
6.2 Supply Chain Analysis
6.2.1 R&D
6.2.2 Manufacturing
6.2.3 Distribution
6.2.4 Marketing & Sales
6.2.5 Post-Sales Monitoring
6.3 Investment Opportunities
6.4 Pricing Analysis
6.5 Demographic Analysis
7 Global Epilepsy Market, by Condition
7.1 Overview
7.1.1 Epilepsy Drug-Resistant/ Intractable Epilepsy
7.1.2 Others
8 Global Epilepsy Market, by Diagnosis & Treatment
8.1 Overview
8.1.1 Diagnosis & Treatment
9 Global Epilepsy Market, by End User
9.1 Overview
10 Global Epilepsy Market, by Region
10.1 Overview
10.2 Americas
10.2.1 North America US CANADA
10.3 Europe
10.3.1 Western Europe Germany France UK
10.3.2 Italy
10.3.3 Spain
10.3.4 Rest of Western Europe
10.3.5 Eastern Europe
10.4 Asia-Pacific Japan China
10.4.2 India
10.4.3 Australia
10.4.4 South Korea
10.4.5 Rest of Asia-Pacific
10.5 Middle East & Africa
10.6 Middle East Saudi Arabia Rest of Middle East
10.6.2 Africa
11 Competitive Landscape
11.1 Company Market Share Analysis
11.1.1 Introduction
12 Company Profile
12.1 LivaNova PLC
12.1.1 Company Overview
12.1.2 Financial Overview
12.1.3 Products/Services Offered
12.1.4 Key Development
12.1.5 SWOT Analysis
12.1.6 Key Strategies
12.2 GlaxoSmithKline PLC
12.2.1 Company Overview
12.2.2 Financial Overview
12.2.3 Products/Services Offered
12.2.4 Key Development
12.2.5 SWOT Analysis
12.2.6 Key Strategies
12.3 Eisai Co. Ltd
12.3.1 Company Overview
12.3.2 Financial Overview
12.3.3 Products/Services Offered
12.3.4 Key Development
12.3.5 SWOT Analysis
12.3.6 Key Strategies
12.4 Pfizer Inc
12.4.1 Company Overview
12.4.2 Financial Overview
12.4.3 Products/Services Offered
12.4.4 Key Developments
12.4.5 SWOT Analysis
12.4.6 Key Strategies
12.5 Medtronic PLC
12.5.1 Company Overview
12.5.2 Financial Overview
12.5.3 Products/Services Offered
12.5.4 Key Developments
12.5.5 SWOT Analysis
12.5.6 Key Strategies
12.6 UCB SA
12.6.1 Company Overview
12.6.2 Financial Overview
12.6.3 Products/Services Offered
12.6.4 Key Developments
12.6.5 SWOT Analysis
12.6.6 Key Strategies
12.7 NeuroPace Inc
12.7.1 Company Overview
12.7.2 Financial Overview
12.7.3 Products/Services Offered
12.7.4 Key Developments
12.7.5 SWOT Analysis
12.7.6 Key Strategies
12.8 GW Pharmaceuticals PLC
12.8.1 Company Overview
12.8.2 Financial Overview
12.8.3 Products/Services Offered
12.8.4 Key Developments
12.8.5 SWOT Analysis
12.8.6 Key Strategies
12.9 Novartis AG
12.9.1 Company Overview
12.9.2 Financial Overview
12.9.3 Products/Services Offered
12.9.4 Key Developments
12.9.5 SWOT Analysis
12.9.6 Key Strategies
12.1 Johnson & Johnson Services Inc.
12.10.1 Company Overview
12.10.2 Financial Overview
12.10.3 Products/Services Offered
12.10.4 Key Developments
12.10.5 SWOT Analysis
12.10.6 Key Strategies
12.11 Abbott Laboratories
12.11.1 Company Overview
12.11.2 Financial Overview
12.11.3 Products/Services Offered
12.11.4 Key Developments
12.11.5 SWOT Analysis
12.11.6 Key Strategies
13 Appendix
13.1 Discussion Blue Print

Additional information


Geography Covered

Date Published